Company profile
Fractyl Health, Inc.
NASDAQ: GUTS · Healthcare · Biotechnology
#1163 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
28DFH 25DQ 29GM —SS 44
v0.1 · 55/100 weight · provisional
↑ market scale, workforce scale · ↓ revenue growth (YoY), return on equity
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$141.0M
Employees
100
as of 2026-09-17
Market cap
$89.2M
as of 2026-09-17
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$141.0M-$141.0M2025
Operating income-$96.8M-$96.8M2025
Total assets$121.4M$121.4M2025
Liabilities$111.9M$111.9M2025
Equity$9.5M$9.5M2025
Revenue trend
FY2024 – FY2025 · USD
FY24
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Fractyl Health, Inc.’s revenue?
Fractyl Health, Inc. booked $0 in FY2025 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
OnKure Therapeutics, Inc.46DVivani Medical, Inc.33DHST Global, Inc.——Revium Recovery Inc.——MAIA Biotechnology, Inc.34DvTv Therapeutics Inc.57CNeighbors
Middlesex →Key facts
CEOHarith Rajagopalan
SectorHealthcare
IndustryBiotechnology
HeadquartersBurlington, MA
ExchangeNASDAQ: GUTS
Employees100
IPO date2024-02-02
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.